Summary & Overview
HCPCS Q4074: Iloprost Inhalation Solution, Unit Dose via DME
HCPCS Level II code Q4074 identifies an FDA-approved, non-compounded iloprost inhalation solution in unit-dose form (up to 20 micrograms) administered through durable medical equipment. This code matters nationally because iloprost is a targeted inhaled vasodilator used in select pulmonary vascular conditions; clear coding ensures correct billing for a high-cost, specialized therapy delivered outside traditional inpatient settings. Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise explanation of what Q4074 represents, typical sites of service, and the clinical context for inhaled iloprost administration. The publication provides benchmark considerations for coverage and payment practices across major national payers, notes common modifiers used with HCPCS Level II supplies, and outlines billing nuances when iloprost is supplied and administered via DME in outpatient and home settings. Where payer-specific policy details are unavailable, the report flags that information as not included. The material is intended for billing managers, revenue cycle teams, clinicians involved in pulmonary vascular care, and policy analysts focused on pharmaceutical and DME billing.
Billing Code Overview
HCPCS Level II code Q4074 describes Iloprost, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, up to 20 micrograms. The service is the provision and administration of an FDA-approved iloprost inhalation solution in unit-dose form using durable medical equipment (DME) for aerosol delivery. The service type is medication administration via inhalation solution supplied as an FDA-approved finished product. The typical site of service is outpatient settings where DME-supported inhalation therapies are provided, including home infusion or home respiratory therapy settings and outpatient infusion or respiratory clinics.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with pulmonary arterial hypertension (PAH) prescribed inhaled iloprost presents to a durable medical equipment (DME) provider for medication delivery training and supply issuance. The patient has a prefilled unit-dose Q4074 iloprost cartridge (up to 20 micrograms) intended for use with a compatible DME nebulizer at home. Clinical workflow: physician documents PAH diagnosis and treatment plan, writes a prescription for inhaled iloprost and DME nebulizer, and transmits to a pharmacy or DME supplier. The supplier verifies prior authorization requirements with payors (for example, Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, BUCA, Medicare), dispenses the FDA-approved unit-dose product, provides device setup and inhalation training, documents device and medication lot numbers, and supplies patient education on administration schedule, adverse effects, and device cleaning. Follow-up includes clinician review of tolerability, dose adherence, and any adverse respiratory events during subsequent cardiology or pulmonary visits.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Standard coding, no modifier | Rarely used; default when no modifier applies |
11 |